Company intelligence / Profile preview

Theranica

Ownership: Private
Development stage: Commercial

Overview

Theranica’s Nerivio device is FDA-cleared for the acute treatment of migraine. Clinical studies have shown it to be effective and safe as a drug-free, non-invasive alternative for migraine management. The company has rapidly scaled its presence in the US market and built one of the world’s largest deidentified migraine registries through real-world data collection from its devices. Its technology is supported by clinical validation and broad insurance coverage, including recent policy adoption by major US health insurers.

Therapeutic areas: Neurology
Modalities: DeviceNon-pharmacological therapyDigital therapeutic
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

Nerivio

Commercial

Indications: Migraine, Chronic migraine, Episodic migraine

Partnerships

BioT Medical (cloud platform/data infrastructure partner)

Beyond the preview

Go deeper on Theranica.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Theranica.

Explore the full profile